Nipple aspirate cytology and pathologic parameters predict residual cancer and nodal involvement after excisional breast biopsy
- PMID: 11747339
- PMCID: PMC2364009
- DOI: 10.1054/bjoc.2001.2151
Nipple aspirate cytology and pathologic parameters predict residual cancer and nodal involvement after excisional breast biopsy
Abstract
We previously demonstrated that abnormal nipple aspirate fluid (NAF) cytology predicted residual breast cancer (RC) and tumour size after excisional biopsy (EB), although normal NAF cytology did not exclude RC. Tumour size correlates with the risk of lymph node (LN) metastases. LN metastases provide prognostic information allowing medical and radiation oncologists to determine the need for adjuvant therapy. We hypothesized that pathologic factors known after EB, combined with NAF cytology, would predict with a high degree of accuracy the presence of RC and LN spread. NAF cytology and pathologic parameters: tumour distance from biopsy margins, multifocal and multicentric disease, sub-type of ductal carcinoma in situ (DCIS) or invasive cancer (IC), grade of DCIS or IC, tumour and specimen size, tumour and biopsy cavity location, presence or absence of extensive DCIS, and biopsy scar distance from the nipple were evaluated bivariately and then by logistic regression (LR) for their association with RC and involved LN (> or = 1 (+) LN, useful to determine chemotherapy need, and > or = 4 (+) LN, useful to determine radiation need to the chest and axilla). Data were analysed using NAF cytology alone, pathologic parameters alone, and NAF cytology and pathologic parameters combined. The combined LR model was superior in predicting residual cancer (94%) to LR models using NAF cytology (36%) or pathologic parameters (75%) alone. When only subjects with normal NAF cytology were evaluated by LR, the model was 92% sensitive in predicting RC. Tumour size and NAF cytology predicted which patients had > or = 1 (+) LN, whereas tumour and specimen size predicted which patients had > or = 4 (+) LN. We propose an algorithm which, if confirmed in a larger study, may allow clinicians to be more selective in their recommendations of re-excision breast biopsy or mastectomy.
Similar articles
-
Nipple aspirate fluid cytology in breast carcinoma.Cancer. 2003 Apr 25;99(2):97-104. doi: 10.1002/cncr.10958. Cancer. 2003. PMID: 12704689
-
Biological markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size.Br J Cancer. 1999 Dec;81(7):1222-7. doi: 10.1038/sj.bjc.6690832. Br J Cancer. 1999. PMID: 10584885 Free PMC article.
-
Nipple aspirate fluid color is associated with breast cancer.Cancer Detect Prev. 2006;30(4):322-8. doi: 10.1016/j.cdp.2006.07.006. Epub 2006 Sep 11. Cancer Detect Prev. 2006. PMID: 16963197
-
Breast carcinoma in situ in a male. Report of a case diagnosed by nipple discharge cytology.Acta Cytol. 1998 May-Jun;42(3):742-4. doi: 10.1159/000331837. Acta Cytol. 1998. PMID: 9622698 Review.
-
259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.Breast Cancer Res Treat. 2008 Jun;109(3):405-16. doi: 10.1007/s10549-007-9668-7. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687650 Review.
Cited by
-
Nipple aspirate fluid and ductoscopy to detect breast cancer.Diagn Cytopathol. 2010 Apr;38(4):244-51. doi: 10.1002/dc.21177. Diagn Cytopathol. 2010. PMID: 19795490 Free PMC article.
-
Biologic markers of breast cancer in nipple aspirate fluid and nipple discharge are associated with clinical findings.Cancer Detect Prev. 2007;31(1):50-8. doi: 10.1016/j.cdp.2006.12.004. Epub 2007 Feb 20. Cancer Detect Prev. 2007. PMID: 17317033 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical